New drug combo shows promise in shrinking lung tumors before surgery
NCT ID NCT07452003
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study is testing a new drug called QL1706, which helps the immune system fight cancer, combined with standard chemotherapy before surgery for people with stage IIB-IIIB non-small cell lung cancer. About 30 participants will receive three cycles of the drug combo, then have surgery to remove the tumor. The goal is to see how many patients have a major response (tumors mostly gone) and to monitor safety and long-term outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QL1706 (a bispecific antibody targeting PD-1 and CTLA-4) plus platinum-based chemotherapy
- What this could lead to
- If successful, this combination could become a new standard perioperative treatment for resectable non-small cell lung cancer, potentially improving survival and reducing recurrence.
- What could go wrong
- This is a small, early-phase study with only 30 participants, so results may not apply broadly. Immune-related side effects are possible, and the treatment may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can standard cancer treatment wake up the immune system? a study investigates.